STRO (STOCKS)
Sutro Biopharma, Inc.
$15.620000
-0.110000 (-0.70%)
Prev close: $15.730000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jane Chung
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $133.07M
- Employees
- 244
- P/E (TTM)
- -0.60
- P/B (TTM)
- -1.52
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
8
Buy
4
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-6.70 | $-4.23 | -2.4727 | -58.49% |
|
Jun 2025 (Q2)
|
$-1.40 | $-4.10 | +2.7026 | +65.88% |
|
Mar 2025 (Q1)
|
$-9.10 | $-7.22 | -1.8835 | -26.10% |
|
Dec 2024 (Q4)
|
$-8.90 | $-8.48 | -0.4229 | -4.99% |
Financial Statements
| Revenues | $105.65M |
| Benefits Costs and Expenses | $320.07M |
| Costs And Expenses | $320.07M |
| Operating Expenses | $291.22M |
| Research and Development | $200.81M |
| Other Operating Expenses | $90.41M |
| Operating Income/Loss | -$185.58M |
| Income/Loss From Continuing Operations After Tax | -$216.77M |
| Income/Loss From Continuing Operations Before Tax | -$214.42M |
| Income Tax Expense/Benefit | $2.34M |
| Net Income/Loss | -$216.77M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$216.77M |
| Net Income/Loss Available To Common Stockholders, Basic | -$216.77M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.61 |
| Diluted Earnings Per Share | -$2.61 |
| Basic Average Shares | 86,086,091 |
| Diluted Average Shares | 86,086,091 |
| Assets | $209.66M |
| Current Assets | $182.11M |
| Noncurrent Assets | $27.55M |
| Fixed Assets | $13.35M |
| Other Non-current Assets | $14.20M |
| Liabilities | $296.93M |
| Current Liabilities | $71.90M |
| Accounts Payable | $7.03M |
| Other Current Liabilities | $64.86M |
| Noncurrent Liabilities | $225.03M |
| Equity | -$87.27M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$87.27M |
| Liabilities And Equity | $209.66M |
| Net Cash Flow From Operating Activities | -$222.53M |
| Net Cash Flow From Operating Activities, Continuing | -$222.53M |
| Net Cash Flow From Investing Activities | $113.80M |
| Net Cash Flow From Investing Activities, Continuing | $113.80M |
| Net Cash Flow From Financing Activities | $84.00K |
| Net Cash Flow From Financing Activities, Continuing | $84.00K |
| Net Cash Flow | -$108.65M |
| Net Cash Flow, Continuing | -$108.65M |
| Comprehensive Income/Loss | -$216.84M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$216.84M |
| Other Comprehensive Income/Loss | -$73.00K |